Physician profile
Alan J Klukowicz
NPI 1912959685
$4,701.09
in general payments reported to CMS, 2019-2025
23 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $902 · 2021: $419 · 2022: $16.08 · 2023: $623 · 2024: $986 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.25 |
| Education | $259.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,454.17 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $939.33 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $461.67 | 2019-2025 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $338.11 | 2019-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $227.60 | 2019-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $179.94 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $155.55 | 2019-2020 | |
| United Therapeutics Corporation | $151.75 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $138.99 | 2020-2025 | |
| Mylan Specialty L.P. | $130.57 | 2019-2024 | Yupelri |
| Insmed, INC. | $116.13 | 2023-2025 | Arikayce, Brinsupri |
| Teva Pharmaceuticals USA, INC. | $112.98 | 2019-2021 | |
| Allergan, INC. | $46.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.09 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $41.45 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.64 | 2019-2020 | |
| Shire North American Group INC | $27.57 | 2019 | |
| Genentech USA, INC. | $27.49 | 2019 | |
| Amgen INC. | $17.99 | 2024 | Tezspire |
| Merck Sharp & Dohme LLC | $17.00 | 2023 | |
| Philips North America LLC | $16.62 | 2025 | Vest Therapy Und |
| Electromed, INC. | $15.38 | 2024 | Smartvest |
| Janssen Pharmaceuticals, INC | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Klukowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.